ACIU Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of 21.59% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -28.55% beat CRISPR Therapeutics AG's return on equity of --.

AC Immune SA has a consensus price target of --, signalling upside risk potential of 282.29%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.75 which suggests that it could grow by 99.68%. Given that AC Immune SA has higher upside potential than CRISPR Therapeutics AG, analysts believe AC Immune SA is more attractive than CRISPR Therapeutics AG.

AC Immune SA has a beta of 1.262, which suggesting that the stock is 26.207% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.069%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $29.5M, which are larger than CRISPR Therapeutics AG quarterly revenues of --. AC Immune SA's net income of $6.4M is higher than CRISPR Therapeutics AG's net income of -$85.9M. Notably, AC Immune SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

MoonLake Immunotherapeutics has a net margin of 21.59% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -28.55% beat MoonLake Immunotherapeutics's return on equity of --.

AC Immune SA has a consensus price target of --, signalling upside risk potential of 282.29%. On the other hand MoonLake Immunotherapeutics has an analysts' consensus of -- which suggests that it could grow by 40.35%. Given that AC Immune SA has higher upside potential than MoonLake Immunotherapeutics, analysts believe AC Immune SA is more attractive than MoonLake Immunotherapeutics.

AC Immune SA has a beta of 1.262, which suggesting that the stock is 26.207% more volatile than S&P 500. In comparison MoonLake Immunotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MoonLake Immunotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. MoonLake Immunotherapeutics pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $29.5M, which are larger than MoonLake Immunotherapeutics quarterly revenues of --. AC Immune SA's net income of $6.4M is higher than MoonLake Immunotherapeutics's net income of -$35.4M. Notably, AC Immune SA's price-to-earnings ratio is -- while MoonLake Immunotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus -- for MoonLake Immunotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Molecular Partners AG has a net margin of 21.59% compared to AC Immune SA's net margin of -2408.81%. AC Immune SA's return on equity of -28.55% beat Molecular Partners AG's return on equity of -37.36%.

AC Immune SA has a consensus price target of --, signalling upside risk potential of 282.29%. On the other hand Molecular Partners AG has an analysts' consensus of $8.79 which suggests that it could grow by 98%. Given that AC Immune SA has higher upside potential than Molecular Partners AG, analysts believe AC Immune SA is more attractive than Molecular Partners AG.

AC Immune SA has a beta of 1.262, which suggesting that the stock is 26.207% more volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $29.5M, which are larger than Molecular Partners AG quarterly revenues of $787.5K. AC Immune SA's net income of $6.4M is higher than Molecular Partners AG's net income of -$19M. Notably, AC Immune SA's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus 25.79x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of 21.59% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -28.55% beat NLS Pharmaceutics's return on equity of --.

AC Immune SA has a consensus price target of --, signalling upside risk potential of 282.29%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12574.27%. Given that NLS Pharmaceutics has higher upside potential than AC Immune SA, analysts believe NLS Pharmaceutics is more attractive than AC Immune SA.

AC Immune SA has a beta of 1.262, which suggesting that the stock is 26.207% more volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $29.5M, which are larger than NLS Pharmaceutics quarterly revenues of --. AC Immune SA's net income of $6.4M is higher than NLS Pharmaceutics's net income of --. Notably, AC Immune SA's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.